Adding Opdivo to Yervoy ups melanoma treatment efficacy–but it ups rate of serious side effects, too

Carly Helfand

The data on Bristol-Myers Squibb's hot new immunotherapy kept rolling out Sunday at ASCO, showing that combining the drug with fellow Bristol cancer-fighter proved more effective in treating advanced than alone. But pairing up the two also increased the risk of , which could offset the tandem's benefits for some patients.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS